Vaccines for the prevention of cardiovascular disease

Vascular Pharmacology

Volumn 45, Issue 5, 2006, Pages 253-257

  Ryan, Una S ^a   Rittershaus, Charles W ^a  

^a AVANT Immunotherapeutics Inc   (United States)

Author keywords

Cardiovascular disease; CETP; CVD; HDL; Vaccine

Indexed keywords

AMYLOID BETA PROTEIN; CANCER VACCINE; CETI VACCINE; CHOLESTEROL ESTER TRANSFER PROTEIN; CONTRACEPTIVE VACCINE; CYSTEINYLGLUTAMINYLTYROSYLISOLEUCYLLYSYLALANYLASPARAGINYLSERYLLYSYLPHENYLALANYLISOLEUCYLGLYCYLISOLEUCYLTHREONYLGLUTAMYLPHENYLALANYLGLYCYLPHENYLALANYLPROLYLGLUTAMYLHISTIDYLLEUCYLLEUCYLVALYLASPARTYLPHENYLALANYLLEUCYLGLUTAMINYLSERYLLEUCYLSERINE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TETANUS TOXIN; VACCINE;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL DIET; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; INFECTION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH SERVICE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PEPTIDES; RABBITS; RANDOMIZED CONTROLLED TRIALS; VACCINES;

EID: 33751091782     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.08.004     Document Type: Article

References (22)

1. Agadjanyan M.G., Ghochikyan A., Petrushina I., et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174 3 (2005) 1580-1586 (Feb 1)
2. Alving C.R., Swartz Jr. G.M., Wassef N.M., Ribas J.L., Herderick E.E., Virmani R., Kolodgie F.D., Matyas G.R., and Cornhill J.F. Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J. Lab. Clin. Med. 127 1 (1996) 40-49 (Jan)
3. American Heart Association. Heart Disease and Stroke Statistics-2005 Update (2004), American Heart Association, Dallas, Tex.
4. Bailey J.M. Cholesterol vaccines. Science 264 5162 (1994) 1067-1068 (May 20)
5. Barter P.J., Brewer H., Chapman J., et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 160-167
6. Brousseau M.E., Diffenderfer M.R., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25 5 (2005) 1057-1064 (May, Electronic publication 2005 Mar 10)
7. Bruckner D., Hafner F.T., Li V., Schmeck C., Telser J., Vakalopoulos A., and Wirtz G. Dibenzodioxocinones-a new class of CETP inhibitors. Bioorg. Med. Chem. Lett. 15 15 (2005) 3611-3614 (Aug 1)
8. Davidson M.H., Maki K., Umporowicz D., et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 169 1 (2003) 113-120 (Jul)
9. De Grooth G.J., Smilde T.J., Van Wissen S., et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Eur. J. Clin. Investig. 34 1 (2004) 21-28 (Jan)
10. Dunbar R.L., and Rader D.J. Current drug options for raising HDL cholesterol. Curr. Treatm. Opt. Cardiovasc. Med. 7 1 (2005) 15-23 (May)
11. Fredrikson G.N., Soderberg I., Lindholm M., et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler. Thromb. Vasc. Biol. 23 5 (2003) 879-884 (May 1, Electronic publication 2003 Mar 20)
12. Gaofu Q., Jun L., Xin Y., et al. Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J. Cardiovasc. Pharmacol. 45 6 (2005) 591-598 (Jun)
13. Gaofu Q., Jun L., Xiuyun Z., et al. Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci. (2005) (Jun 14; [Electronic publication ahead of print])
14. Gero S. Some data on the influence of cholesterol atherosclerosis by immunological means. Rev. Atheroscler. (Paris) 9 1 (1967) 194-198 (Suppl 1)
15. Huser M.A., Evans T.S., and Berger V. Medication adherence trends with statins. Adv. Ther. 22 2 (2005) 163-171 (Mar-Apr)
16. Kuivenhoven J.A., de Grooth G.J., Kawamura H., Klerkx A.H., Wilhelm F., Trip M.D., and Kastelein J.J. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 95 9 (2005) 1085-1088 (May 1)
17. Moriyama Y., Okamura T., Inazu A., et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27 5 Pt 1 (1998) 659-667 (Sep-Oct)
18. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106 25 (2002) 3143-3421 (Dec 17)
19. Naz R.K. Contraceptive vaccines. Drugs 65 5 (2005) 593-603
20. Nilsson J., Hansson G.K., and Shah P.K. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler. Thromb. Vasc. Biol. 25 1 (2005) 18-28 (Jan, Electronic publication 2004 Oct 28)
21. Nyman J.A., Martinson M.S., Nelson D., et al., VA-HIT Study Group. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. Arch. Intern. Med. 162 2 (2002) 177-182 (Jan 28)
22. Rittershaus C.W., Miller D.P., Thomas L.J., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20 9 (2000) 2106-2112 (Sep)